## Supplementary Materials

**Table S1.** Information of the standard materials.

| Standard Materials     | Lot Number   | Content  |
|------------------------|--------------|----------|
| Caffeic acid           | 110885-200102| 97.2%    |
| Phillyrin              | Z17A8X34077  | 98%      |
| Arctiin                | Z11D6B7394   | 98%      |
| Neochlorogenic acid    | P13O8F45676  | 98%      |
| Chlorogenic acid       | Y24J7K16726  | 98%      |
| Isochlorogenic acid A  | Y24N8Y49009  | 98%      |
| Isochlorogenic acid C  | P25J6F1794   | 98%      |
| Hesperidin             | 110721-201014| 95.1%    |
| Rutin                  | 100080-201409| 91.9%    |
| Liquiritin             | 111610-201106| 93.7%    |
| Cynaroside             | 111720-201408| 94.9%    |
| Forsythoside A         | 111810-201707| 97.2%    |

**Table S2.** The KEGG enrichment results of Yinqiao powder in treating for COVID-19.

| GO         | Description                                                  | Count | %     | LogP     |
|------------|--------------------------------------------------------------|-------|-------|----------|
| hsa05200   | Pathways in cancer                                           | 40    | 50.00 | -48.09   |
| hsa05417   | Lipid and atherosclerosis                                    | 31    | 38.75 | -45.52   |
| hsa04933   | AGE-RAGE signaling pathway in diabetic complications          | 23    | 28.75 | -38.45   |
| hsa05163   | Human cytomegalovirus infection                              | 24    | 30.00 | -31.56   |
| hsa05167   | Kaposi sarcoma-associated herpesvirus infection              | 22    | 27.50 | -29.47   |
| hsa04657   | IL-17 signaling pathway                                      | 18    | 22.50 | -28.39   |
| hsa05205   | Proteoglycans in cancer                                      | 21    | 26.25 | -27.14   |
| hsa05418   | Fluid shear stress and atherosclerosis                       | 19    | 23.75 | -27.00   |
| hsa04668   | TNF signaling pathway                                         | 18    | 22.50 | -26.91   |
| hsa05215   | Prostate cancer                                              | 17    | 21.25 | -26.09   |
| hsa05165   | Human papillomavirus infection                               | 23    | 28.75 | -25.83   |
| hsa05161   | Hepatitis B                                                  | 19    | 23.75 | -25.67   |
| hsa05145   | Toxoplasmosis                                                | 17    | 21.25 | -24.95   |
| hsa05171   | Coronavirus disease - COVID-19                               | 20    | 25.00 | -24.28   |
| hsa05142   | Chagas disease                                               | 16    | 20.00 | -23.72   |
| hsa04151   | PI3K-Akt signaling pathway                                   | 22    | 27.50 | -23.60   |
| hsa04066   | HIF-1 signaling pathway                                      | 16    | 20.00 | -23.23   |
| hsa05164   | Influenza A                                                  | 17    | 21.25 | -21.68   |
| hsa01521   | EGFR tyrosine kinase inhibitor resistance                    | 14    | 17.50 | -21.56   |
| hsa05162   | Measles                                                      | 16    | 20.00 | -21.46   |
| hsa05166   | Human T-cell leukemia virus 1 infection                      | 18    | 22.50 | -21.33   |
| hsa05160   | Hepatitis C                                                  | 16    | 20.00 | -20.58   |
| hsa05169   | Epstein-Barr virus infection                                  | 17    | 21.25 | -20.42   |
| hsa05206   | MicroRNAs in cancer                                          | 19    | 23.75 | -20.21   |
| hsa01522   | Endocrine resistance                                         | 14    | 17.50 | -20.16   |
| hsa05225   | Hepatocellular carcinoma                                    | 16    | 20.00 | -20.09   |
| ID     | Annotation                                                                 | Count | Avg | Range   |
|--------|---------------------------------------------------------------------------|-------|-----|---------|
| hsa05207 | Chemical carcinogenesis - receptor activation                             | 17    | 21.25 | -20.06 |
| hsa05212 | Pancreatic cancer                                                          | 13    | 16.25 | -19.82 |
| hsa05222 | Small cell lung cancer                                                    | 13    | 16.25 | -18.67 |
| hsa04210 | Apoptosis                                                                 | 14    | 17.50 | -18.08 |
| hsa04620 | Toll-like receptor signaling pathway                                       | 13    | 16.25 | -17.94 |
| hsa04625 | C-type lectin receptor signaling pathway                                   | 13    | 16.25 | -17.94 |
| hsa04936 | Alcoholic liver disease                                                   | 14    | 17.50 | -17.81 |
| hsa04010 | MAPK signaling pathway                                                    | 17    | 21.25 | -17.63 |
| hsa04218 | Cellular senescence                                                       | 14    | 17.50 | -17.22 |
| hsa05210 | Colorectal cancer                                                         | 12    | 15.00 | -17.18 |
| hsa04071 | Sphingolipid signaling pathway                                            | 13    | 16.25 | -17.15 |
| hsa04919 | Thyroid hormone signaling pathway                                         | 13    | 16.25 | -17.05 |
| hsa05170 | Human immunodeficiency virus 1 infection                                   | 15    | 18.75 | -16.87 |
| hsa05022 | Pathways of neurodegeneration - multiple diseases                         | 19    | 23.75 | -16.72 |
| hsa04926 | Relaxin signaling pathway                                                 | 13    | 16.25 | -16.68 |
| hsa04068 | FoxO signaling pathway                                                    | 13    | 16.25 | -16.59 |
| hsa05208 | Chemical carcinogenesis - reactive oxygen species                         | 15    | 18.75 | -16.54 |
| hsa04917 | Prolactin signaling pathway                                               | 11    | 13.75 | -16.38 |
| hsa05152 | Tuberculosis                                                              | 14    | 17.50 | -16.34 |
| hsa05135 | Yersinia infection                                                        | 13    | 16.25 | -16.33 |
| hsa05146 | Amoebiasis                                                                | 12    | 15.00 | -16.25 |
| hsa04621 | NOD-like receptor signaling pathway                                       | 14    | 17.50 | -16.20 |
| hsa01524 | Platinum drug resistance                                                 | 11    | 13.75 | -16.16 |
| hsa04115 | p53 signaling pathway                                                    | 11    | 13.75 | -16.16 |
| hsa04064 | NF-kappa B signaling pathway                                              | 12    | 15.00 | -16.14 |
| hsa05214 | Glioma                                                                    | 11    | 13.75 | -16.03 |
| hsa05220 | Chronic myeloid leukemia                                                  | 11    | 13.75 | -15.96 |
| hsa04062 | Chemokine signaling pathway                                               | 14    | 17.50 | -15.94 |
| hsa04659 | Th17 cell differentiation                                                 | 12    | 15.00 | -15.94 |
| hsa05140 | Leishmaniasis                                                             | 11    | 13.75 | -15.89 |
| hsa05131 | Shigelliosis                                                              | 15    | 18.75 | -15.88 |
| hsa05132 | Salmonella infection                                                      | 15    | 18.75 | -15.83 |
| hsa04510 | Focal adhesion                                                            | 14    | 17.50 | -15.66 |
| hsa04932 | Non-alcoholic fatty liver disease                                         | 13    | 16.25 | -15.62 |
| hsa04370 | VEGF signaling pathway                                                    | 10    | 12.50 | -15.27 |
| hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer                    | 11    | 13.75 | -15.17 |
| hsa04380 | Osteoclast differentiation                                                | 12    | 15.00 | -15.03 |
| hsa05323 | Rheumatoid arthritis                                                      | 11    | 13.75 | -14.95 |
| hsa05219 | Bladder cancer                                                            | 9     | 11.25 | -14.88 |
| hsa05223 | Non-small cell lung cancer                                                | 10    | 12.50 | -14.35 |
| hsa05130 | Pathogenic Escherichia coli infection                                     | 13    | 16.25 | -14.25 |
| hsa05133 | Pertussis                                                                 | 10    | 12.50 | -14.10 |
| hsa04935 | Growth hormone synthesis, secretion and action                            | 11    | 13.75 | -13.73 |
| hsa05213 | Endometrial cancer                                                        | 9     | 11.25 | -13.41 |
| hsa05202 | Transcriptional misregulation in cancer                                   | 12    | 15.00 | -12.87 |
| hsa05224 | Breast cancer                                                             | 11    | 13.75 | -12.71 |
| hsa04660 | T cell receptor signaling pathway                                         | 10    | 12.50 | -12.69 |
| hsa05226 | Gastric cancer                                                            | 11    | 13.75 | -12.64 |
| hsa05203 | Viral carcinogenesis                                                      | 12    | 15.00 | -12.58 |
| hsa05218 | Melanoma                                                                  | 9     | 11.25 | -12.52 |
| hsa05020 | Prion disease                                                             | 13    | 16.25 | -12.43 |
| hsa04915 | Estrogen signaling pathway                                                | 10    | 12.50 | -11.45 |
| hsa04371 | Apelin signaling pathway                                                  | 10    | 12.50 | -11.41 |
| Gene Symbol | Pathway Name                                      | Rank | normalized value | q-value |
|------------|--------------------------------------------------|------|------------------|---------|
| hsa04921  | Oxytocin signaling pathway                      | 10   | 12.50            | -10.97  |
| hsa04931  | Insulin resistance                              | 9    | 11.25            | -10.89  |
| hsa04630  | JAK-STAT signaling pathway                      | 10   | 12.50            | -10.75  |
| hsa04726  | Serotonergic synapse                            | 9    | 11.25            | -10.64  |
| hsa05010  | Alzheimer disease                               | 13   | 16.25            | -10.57  |
| hsa05144  | Malaria                                         | 7    | 8.75             | -10.20  |
| hsa04664  | Viral protein interaction with cytokine and cytokine receptor | 8    | 10.00            | -9.59   |
| hsa04931  | Parathyroid hormone synthesis, secretion and action | 8    | 10.00            | -9.38   |
| hsa04014  | Fc epsilon RI signaling pathway                 | 7    | 8.75             | -9.22   |
| hsa05168  | Ras signaling pathway                           | 10   | 12.50            | -9.22   |
| hsa05168  | Herpes simplex virus 1 infection                | 13   | 16.25            | -9.21   |
| hsa05216  | Thyroid cancer                                  | 6    | 7.50             | -9.21   |
| hsa04725  | Cholinergic synapse                             | 8    | 10.00            | -9.16   |
| hsa05230  | Central carbon metabolism in cancer             | 7    | 8.75             | -9.13   |
| hsa04722  | Neurotrophin signaling pathway                  | 8    | 10.00            | -8.98   |
| hsa04662  | B cell receptor signaling pathway               | 7    | 8.75             | -8.64   |
| hsa05014  | Amyotrophic lateral sclerosis                   | 11   | 13.75            | -8.48   |
| hsa04920  | Diabetic cardiomyopathy                        | 9    | 11.25            | -8.44   |
| hsa04140  | Autophagy-animal                                | 8    | 10.00            | -8.39   |
| hsa04658  | Th1 and Th2 cell differentiation                | 7    | 8.75             | -8.29   |
| hsa04912  | GnRH signaling pathway                          | 7    | 8.75             | -8.26   |
| hsa04060  | Cytokine-cytokine receptor interaction          | 10   | 12.50            | -8.21   |
| hsa05134  | Legionellosis                                   | 6    | 7.50             | -8.03   |
| hsa04217  | Necroptosis                                     | 8    | 10.00            | -7.98   |
| hsa05415  | Viral myocarditis                               | 6    | 7.50             | -7.89   |
| hsa04929  | GnRH secretion                                  | 6    | 7.50             | -7.72   |
| hsa05321  | Inflammatory bowel disease                     | 6    | 7.50             | -7.68   |
| hsa05221  | Acute myeloid leukemia                          | 6    | 7.50             | -7.60   |
| hsa05211  | Renal cell carcinoma                            | 6    | 7.50             | -7.52   |
| hsa04622  | RIG-I-like receptor signaling pathway           | 6    | 7.50             | -7.49   |
| hsa05120  | Epithelial cell signaling in Helicobacter pylori infection | 6    | 7.50             | -7.49   |
| hsa04611  | Platelet activation                             | 7    | 8.75             | -7.39   |
| hsa04613  | Neutrophil extracellular trap formation         | 8    | 10.00            | -7.38   |
| hsa04110  | Cell cycle                                      | 7    | 8.75             | -7.34   |
| hsa05143  | African trypanosomiasis                         | 5    | 6.25             | -7.33   |
| hsa04650  | Natural killer cell mediated cytotoxicity       | 7    | 8.75             | -7.22   |
| hsa04728  | Dopaminergic synapse                            | 7    | 8.75             | -7.20   |
| hsa04015  | Rap1 signaling pathway                          | 8    | 10.00            | -7.04   |
| hsa04540  | Gap junction                                    | 6    | 7.50             | -6.89   |
| hsa04723  | Retrograde endocannabinoid signaling            | 7    | 8.75             | -6.86   |
| hsa04072  | Phospholipase D signaling pathway               | 7    | 8.75             | -6.86   |
| hsa04211  | Longevity regulating pathway                    | 6    | 7.50             | -6.86   |
| hsa04261  | Adrenergic signaling in cardiomyocytes          | 7    | 8.75             | -6.82   |
| hsa04934  | Cushing syndrome                                | 7    | 8.75             | -6.72   |
| hsa04666  | Fc gamma R-mediated phagocytosis                | 6    | 7.50             | -6.63   |
| hsa04713  | Circadian entrainment                           | 6    | 7.50             | -6.63   |
| hsa04916  | Melanogenesis                                   | 6    | 7.50             | -6.53   |
| hsa04914  | Progesterone-mediated oocyte maturation         | 6    | 7.50             | -6.50   |
| hsa05012  | Parkinson disease                               | 8    | 10.00            | -6.26   |
| ID       | Pathway                                      | Rank | Score | Fold Change |
|----------|----------------------------------------------|------|-------|-------------|
| hsa04720 | Long-term potentiation                       | 5    | 6.25  | -6.01       |
| hsa05031 | Amphetamine addiction                       | 5    | 6.25  | -5.95       |
| hsa04920 | Adipocytokine signaling pathway              | 5    | 6.25  | -5.95       |
| hsa01523 | Antifolate resistance                        | 4    | 5.00  | -5.93       |
| hsa04918 | Thyroid hormone synthesis                   | 5    | 6.25  | -5.77       |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells | 6    | 7.50  | -5.64       |
| hsa04960 | Aldosterone-regulated sodium reabsorption   | 4    | 5.00  | -5.55       |
| hsa04610 | Complement and coagulation cascades         | 5    | 6.25  | -5.50       |
| hsa04020 | Calcium signaling pathway                   | 7    | 8.75  | -5.45       |
| hsa04310 | Wnt signaling pathway                       | 6    | 7.50  | -5.25       |
| hsa04672 | Intestinal immune network for IgA production| 4    | 5.00  | -5.05       |
| hsa04961 | Endocrine and other factor-regulated calcium reabsorption | 4    | 5.00  | -4.92       |
| hsa04670 | Leukocyte transendothelial migration        | 5    | 6.25  | -4.87       |
| hsa04724 | Glutamatergic synapse                       | 5    | 6.25  | -4.87       |
| hsa04340 | Hedgehog signaling pathway                  | 4    | 5.00  | -4.82       |
| hsa04730 | Long-term depression                        | 4    | 5.00  | -4.70       |
| hsa04213 | Longevity regulating pathway - multiple species | 4    | 5.00  | -4.64       |
| hsa04114 | Oocyte meiosis                              | 5    | 6.25  | -4.58       |
| hsa00220 | Arginine biosynthesis                       | 3    | 3.75  | -4.58       |
| hsa04270 | Vascular smooth muscle contraction          | 5    | 6.25  | -4.53       |
| hsa04910 | Insulin signaling pathway                   | 5    | 6.25  | -4.49       |
| hsa04141 | Protein processing in endoplasmic reticulum | 5    | 6.25  | -4.03       |
| hsa04350 | TGF-beta signaling pathway                  | 4    | 5.00  | -3.93       |
| hsa04750 | Inflammatory mediator regulation of TRP channels | 4    | 5.00  | -3.86       |
| hsa05330 | Allograft rejection                         | 3    | 3.75  | -3.85       |
| hsa05016 | Huntington disease                          | 6    | 7.50  | -3.78       |
| hsa05332 | Graft-versus-host disease                   | 3    | 3.75  | -3.72       |
| hsa04930 | Type II diabetes mellitus                   | 3    | 3.75  | -3.60       |
| hsa04810 | Regulation of actin cytoskeleton            | 5    | 6.25  | -3.54       |
| hsa04152 | AMPK signaling pathway                      | 4    | 5.00  | -3.53       |
| hsa04024 | cAMP signaling pathway                      | 5    | 6.25  | -3.51       |
| hsa04913 | Ovarian steroidogenesis                     | 3    | 3.75  | -3.47       |
| hsa00330 | Arginine and proline metabolism             | 3    | 3.75  | -3.47       |
| hsa04923 | Regulation of lipolysis in adipocytes       | 3    | 3.75  | -3.35       |
| hsa04623 | Cytosolic DNA-sensing pathway               | 3    | 3.75  | -3.20       |
| hsa05217 | Basal cell carcinoma                        | 3    | 3.75  | -3.20       |
| hsa04390 | Hippo signaling pathway                     | 4    | 5.00  | -3.09       |
| hsa05204 | Chemical carcinogenesis - DNA adducts       | 3    | 3.75  | -3.08       |
| hsa04520 | Adherens junction                           | 3    | 3.75  | -3.05       |
| hsa04137 | Mitophagy - animal                          | 3    | 3.75  | -3.03       |
| hsa00982 | Drug metabolism - cytochrome P450            | 3    | 3.75  | -3.03       |
| hsa04022 | cGMP-PKG signaling pathway                  | 4    | 5.00  | -2.99       |
| hsa04971 | Gastric acid secretion                      | 3    | 3.75  | -2.96       |
| hsa04612 | Antigen processing and presentation         | 3    | 3.75  | -2.93       |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3    | 3.75  | -2.93       |
| hsa00983 | Drug metabolism - other enzymes             | 3    | 3.75  | -2.90       |
| hsa04360 | Axon guidance                               | 4    | 5.00  | -2.85       |
| hsa04911 | Insulin secretion                           | 3    | 3.75  | -2.81       |
| hsa04727 | GABAergic synapse                           | 3    | 3.75  | -2.76       |
| hsa04976 | Bile secretion                              | 3    | 3.75  | -2.76       |
| hsa05410 | Hypertrophic cardiomyopathy                 | 3    | 3.75  | -2.75       |
| hsa05032 | Morphine addiction                          | 3    | 3.75  | -2.74       |
| hsa04970 | Salivary secretion                          | 3    | 3.75  | -2.72       |
### Table S3. Similarity evaluation of 10 batches of Yinqiao powder.

|     | S1   | S2   | S3   | S4   | S5   | S6   | S7   | S8   | S9   | S10  | Reference |
|-----|------|------|------|------|------|------|------|------|------|------|-----------|
| S1  | 1.000| 0.983| 0.976| 0.973| 0.983| 0.993| 0.993| 0.977| 0.994| 0.984| 0.990     |
| S2  | 0.983| 1.000| 0.987| 0.986| 0.983| 0.993| 0.993| 0.994| 0.996| 0.987| 0.994     |
| S3  | 0.976| 0.987| 1.000| 0.999| 0.996| 0.993| 0.993| 0.992| 0.988| 0.995| 0.996     |
| S4  | 0.973| 0.986| 0.999| 1.000| 0.994| 0.991| 0.991| 0.992| 0.986| 0.994| 0.995     |
| S5  | 0.983| 0.983| 0.996| 0.994| 1.000| 0.993| 0.993| 0.988| 0.989| 0.998| 0.996     |
| S6  | 0.993| 0.993| 0.993| 0.991| 0.993| 1.000| 1.000| 0.993| 0.998| 0.994| 0.999     |
| S7  | 0.993| 0.993| 0.993| 0.991| 0.993| 1.000| 1.000| 0.993| 0.998| 0.994| 0.999     |
| S8  | 0.977| 0.994| 0.992| 0.992| 0.988| 0.993| 0.993| 1.000| 0.992| 0.990| 0.995     |
| S9  | 0.994| 0.996| 0.988| 0.986| 0.989| 0.998| 0.998| 0.992| 1.000| 0.990| 0.997     |
| S10 | 0.984| 0.987| 0.995| 0.994| 0.998| 0.994| 0.994| 0.990| 0.990| 1.000| 0.997     |
| Reference | 0.990 | 0.994 | 0.996 | 0.995 | 0.996 | 0.999 | 0.999 | 0.995 | 0.997 | 0.997 | 1.000 |

### Table S4. Relative retention time and RSD of common peaks.

|     | S1   | S2   | S3   | S4   | S5   | S6   | S7   | S8   | S9   | S10  | RSD/% |
|-----|------|------|------|------|------|------|------|------|------|------|-------|
| 1   | 0.118| 0.117| 0.116| 0.116| 0.117| 0.117| 0.117| 0.117| 0.117| 0.117| 0.14  |
| 2   | 0.220| 0.220| 0.220| 0.220| 0.219| 0.219| 0.220| 0.219| 0.220| 0.220| 0.05  |
| 3   | 0.281| 0.281| 0.281| 0.281| 0.280| 0.280| 0.280| 0.280| 0.280| 0.281| 0.11  |
| 4   | 0.396| 0.396| 0.395| 0.395| 0.395| 0.395| 0.395| 0.395| 0.395| 0.395| 0.07  |
| 5   | 0.429| 0.429| 0.428| 0.428| 0.428| 0.428| 0.428| 0.428| 0.428| 0.429| 0.08  |
| 6   | 0.454| 0.453| 0.453| 0.453| 0.452| 0.453| 0.453| 0.453| 0.453| 0.453| 0.08  |
| 7   | 0.463| 0.463| 0.463| 0.462| 0.462| 0.462| 0.462| 0.462| 0.462| 0.463| 0.09  |
| 8   | 0.585| 0.583| 0.583| 0.583| 0.583| 0.583| 0.583| 0.583| 0.583| 0.583| 0.10  |
| 9   | 0.710| 0.708| 0.708| 0.708| 0.707| 0.707| 0.708| 0.707| 0.707| 0.707| 0.11  |
| 10  | 0.741| 0.739| 0.739| 0.739| 0.738| 0.739| 0.739| 0.739| 0.739| 0.739| 0.11  |
| 11  | 0.883| 0.881| 0.881| 0.881| 0.881| 0.881| 0.881| 0.881| 0.881| 0.881| 0.09  |
| 12  | 0.929| 0.928| 0.928| 0.927| 0.927| 0.927| 0.927| 0.927| 0.927| 0.928| 0.08  |
| 13  | 0.980| 0.979| 0.980| 0.979| 0.979| 0.979| 0.979| 0.979| 0.979| 0.980| 0.05  |
| 14  | 1.000| 1.000| 1.000| 1.000| 1.000| 1.000| 1.000| 1.000| 1.000| 1.000| 0.00  |
| 15  | 1.055| 1.051| 1.052| 1.052| 1.051| 1.052| 1.052| 1.052| 1.052| 1.053| 0.09  |
| 16  | 1.138| 1.136| 1.136| 1.136| 1.136| 1.136| 1.136| 1.136| 1.136| 1.136| 0.06  |
| 17  | 1.337| 1.335| 1.335| 1.334| 1.334| 1.334| 1.334| 1.334| 1.334| 1.335| 0.08  |
| 18  | 1.385| 1.382| 1.383| 1.383| 1.384| 1.384| 1.384| 1.384| 1.383| 1.383| 0.06  |
| 19  | 1.403| 1.401| 1.401| 1.400| 1.400| 1.400| 1.401| 1.401| 1.400| 1.402| 0.06  |
| NO. | t   | R    | A    | NO. | t   | R    | A    |
|-----|-----|------|------|-----|-----|------|------|
| 1   | 6.152 | 1.518 | 16   | 59.610 | 2.812 |
| 2   | 11.520 | 4.579 | 17   | 70.031 | 9.909 |
| 3   | 14.717 | 0.423 | 18   | 72.586 | 1.023 |
| 4   | 20.736 | 1.339 | 19   | 73.497 | 0.506 |
| 5   | 22.469 | 1.612 | 20   | 81.585 | 0.465 |
| 6   | 23.764 | 3.972 | 21   | 83.037 | 2.748 |
| 7   | 24.259 | 17.379 | 22   | 84.476 | 0.955 |
| 8   | 30.593 | 0.913 | 23   | 87.582 | 0.864 |
| 9   | 37.138 | 0.205 | 24   | 90.918 | 0.745 |
| 10  | 38.776 | 7.616 | 25   | 102.826 | 2.467 |
| 11  | 46.233 | 3.457 | 26   | 105.913 | 13.022 |
| 12  | 48.677 | 2.287 | 27   | 107.822 | 1.252 |
| 13  | 51.391 | 1.599 | 28   | 119.678 | 2.250 |
| 14  | 52.482 | 23.556 | 29   | 121.231 | 1.808 |
| 15  | 55.217 | 0.683 |

Table S5. Median retention time and average peak area of common peaks.

| Component | Total | Variance% | Cumulative% |
|-----------|-------|-----------|-------------|
| 1         | 13.667 | 47.129    | 47.129       |
| 2         | 7.939  | 27.375    | 74.504       |
| 3         | 2.900  | 9.999     | 84.503       |
| 4         | 2.170  | 7.481     | 91.984       |
| 5         | 1.126  | 3.884     | 95.868       |
| 6         | 0.659  | 2.272     | 98.140       |
| 7         | 0.333  | 1.147     | 99.286       |
| 8         | 0.186  | 0.643     | 99.929       |
| 9         | 0.021  | 0.071     | 100.000      |
| 10        | 8.678E-16 | 2.992E-15 | 100.000     |
### Table S7. Results of method validation.

| Methodology | RSD/% | 237 nm Forsythoside A | 237 nm Arctiin | 327 nm Forsythoside A | 327 nm Neochlorogenic acid | 327 nm Chlorogenic acid | 327 nm Isochlorogenic acid A | 327 nm Isochlorogenic acid C |
|-------------|-------|-----------------------|---------------|-----------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| Precision   | 1.40  | 1.70                  | 1.48          | 1.36                  | 1.42                      | 1.36                      | 1.34                      | 1.54                      |
| Stability   | 0.55  | 0.20                  | 0.11          | 0.52                  | 0.42                      | 0.12                      | 0.33                      | 0.97                      |
| Repeatability | 2.72  | 1.99                  | 1.15          | 2.61                  | 2.21                      | 2.28                      | 2.61                      | 2.70                      |
| Accuracy    | 98.31 | 98.58                 | 99.73         | 96.32                 | 101.44                    | 99.67                     | 101.79                    | 99.44                     |

### Table S8. RCFs in different instruments and columns.

| Instrument   | Column              | RCF 237 nm | RCF 327 nm |
|--------------|---------------------|------------|------------|
|              |                     | 237 nm     | 327 nm     |
|              | Phiylrin Arctiin    | Neochlorogenic acid | Chlorogenic acid | Isochlorogenic acid A | Isochlorogenic acid C |
| Thermo       | Hypersil ODS2       | 0.836      | 0.856      | 2.190                | 1.611                | 1.564                | 1.782                |
| UltiMate3000-1 | Thermo Syncronis C18 | 0.832      | 0.865      | 2.187                | 1.611                | 1.566                | 1.795                |
| UltiMate3000-2 | Hypersil ODS2       | 0.838      | 0.867      | 2.187                | 1.614                | 1.566                | 1.795                |
| Mean         |                     | 0.836      | 0.861      | 2.188                | 1.612                | 1.565                | 1.787                |
| RSD          |                     | 0.37%      | 0.68%      | 0.08%                | 0.09%                | 0.07%                | 0.53%                |